

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM697804

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
THE LYNX GROUP, LLC		12/27/2021	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	MidCap Financial Trust, as Collateral Agent		
Street Address:	7255 Woodmont Avenue, Suite 300		
Internal Address:	c/o MidCap Financial Services, LLC, as Servicer		
City:	Bethesda		
State/Country:	MARYLAND		
Postal Code:	20814		
Entity Type:	Statutory Trust: DELAWARE		
PROPERTY NUMBERS Total: 47			
Property Type	Number	Word Mark	
Registration Number:	3529391	AMERICAN HEALTH & DRUG BENEFITS	
Registration Number:	3503239	AMERICAN HEALTH & DRUG BENEFITS	
Registration Number:	5357418	CONQUER	
Registration Number:	5084500	CONSIDERATIONS IN LYMPHOMA	
Registration Number:	5098044	CONSIDERATIONS IN MULTIPLE MYELOMA	
Registration Number:	6230267	DERMATOLOGY PRACTICE MANAGEMENT	
Registration Number:	6285019	DERMATOLOGY PRACTICE MANAGEMENT	
Registration Number:	6230268	DERMATOLOGY PRACTICE MANAGEMENT	
Registration Number:	4029791	FOSTERING A DIALOGUE TO IMPROVE PATIENTC	
Registration Number:	4749801	IMMUNOTHERAPY IN ONCOLOGY	
Registration Number:	3617783	INTERACTIVE PEER-TO-PEER DISCUSSIONS IN	
Registration Number:	6384889	JOURNAL OF ONCOLOGY NAVIGATION & SURVIVO	
Registration Number:	6384890	JOURNAL OF ONCOLOGY NAVIGATION & SURVIVO	
Registration Number:	6274430	ONCOLOGY PRACTICE MANAGEMENT	
Registration Number:	6191739	ONCOLOGY PRACTICE MANAGEMENT	
Registration Number:	6191738	ONCOLOGY PRACTICE MANAGEMENT	
Registration Number:	6218683	RHEUMATOLOGY PRACTICE MANAGEMENT	
Registration Number:	6230269	RHEUMATOLOGY PRACTICE MANAGEMENT	
		TRADEMARK	

CH \$1190.00 3529391

Property Type	Number	Word Mark
Registration Number:	4290377	RX PROFILER
Registration Number:	4188210	RX PROFILER
Registration Number:	4024121	THE JOURNAL OF ONCOLOGY NAVIGATION & SUR
Registration Number:	4017380	THE ONCOLOGY NURSE-APN/PA
Registration Number:	4014148	THE ONCOLOGY NURSE-APN/PA
Registration Number:	4017379	THE ONCOLOGY NURSE-APN/PA
Registration Number:	4017381	THE ONCOLOGY NURSE-APN/PA
Registration Number:	3555609	THE ONCOLOGY PHARMACIST
Registration Number:	3555608	THE ONCOLOGY PHARMACIST
Registration Number:	4107003	THE UROLOGY NURSE-NP/PA
Registration Number:	4107004	THE UROLOGY NURSE-NP/PA
Registration Number:	3918281	VALUE-BASED CANCER CARE
Registration Number:	3918282	VALUE-BASED CANCER CARE
Serial Number:	90706065	AMYLOIDOSIS NEWS
Serial Number:	90787392	CONQUER THE PATIENT VOICE RARE DISEASE E
Serial Number:	97154897	IMMUNOTHERAPY IN ONCOLOGY
Serial Number:	90705915	JOURNAL OF HEMATOLOGY ONCOLOGY PHARMACY
Serial Number:	90705904	JOURNAL OF HEMATOLOGY ONCOLOGY PHARMACY
Serial Number:	90779730	RESOURCE NAVIGATOR
Serial Number:	85539871	RHEUMATOLOGY PRACTICE MANAGEMENT
Serial Number:	90021974	STRATEGIX
Serial Number:	90975741	STRATEGIX
Serial Number:	90051366	STRATEGIX
Serial Number:	90975742	STRATEGIX
Serial Number:	90021979	THE LYNX GROUP
Serial Number:	90051354	THE LYNX GROUP
Serial Number:	85537400	UROLOGY PRACTICE MANAGEMENT
Serial Number:	85537390	UROLOGY PRACTICE MANAGEMENT
Serial Number:	85537462	UROLOGY PRACTICE MANAGEMENT

CORRESPONDENCE DATA

Fax Number: 6175269899

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6175269628

Email: cslattery@proskauer.com

Correspondent Name: Christine Slattery

Address Line 1: Proskauer Rose LLP

Address Line 2: One International Place, 23rd Floor

Address Line 4: Boston, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	11964.195
NAME OF SUBMITTER:	Christine Slattery
SIGNATURE:	/Christine Slattery/
DATE SIGNED:	12/27/2021

Total Attachments: 9

source=[11] Trademark Security Agreement#page1.tif
source=[11] Trademark Security Agreement#page2.tif
source=[11] Trademark Security Agreement#page3.tif
source=[11] Trademark Security Agreement#page4.tif
source=[11] Trademark Security Agreement#page5.tif
source=[11] Trademark Security Agreement#page6.tif
source=[11] Trademark Security Agreement#page7.tif
source=[11] Trademark Security Agreement#page8.tif
source=[11] Trademark Security Agreement#page9.tif

TRADEMARK SECURITY AGREEMENT

This **TRADEMARK SECURITY AGREEMENT** (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “IP Security Agreement”), dated as of December 27, 2021, is among THE LYNX GROUP, LLC (the “Grantor”) and MidCap Financial Trust (“MidCap”), as collateral agent (the “Collateral Agent”) for the Secured Parties (as defined in the Credit Agreement referred to below).

WHEREAS, Amplity Parent, Inc. (f/k/a PHS Buyer, Inc.), a Delaware corporation (the “Borrower”), Amplity Intermediate, Inc. (f/k/a PHS Intermediate, Inc.), a Delaware corporation (“Holdings”) and the Loan Parties (as defined therein) from time to time party thereto, have entered into the Amended and Restated Credit Agreement, dated as of December 27, 2021 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), with the lenders from time to time party thereto (collectively, the “Lenders” and individually, a “Lender”), the L/C Issuers (as defined therein) party thereto and MidCap Financial Trust (“MidCap”), as Administrative Agent, Collateral Agent, a Lender, Swing Line Lender and an L/C Issuer. Capitalized terms defined in the Credit Agreement or in the Security Agreement (as defined below) and not otherwise defined herein are used herein as defined in the Credit Agreement or the Security Agreement, as the case may be (and in the event of a conflict, the applicable definition shall be the one given to such term in the Security Agreement).

WHEREAS, as a condition precedent to the making of the Loans by the Lenders from time to time, the Grantor has executed and delivered that certain Supplement to U.S. Security Agreement, dated as of December 27, 2021 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”), among the Grantors from time to time party thereto and the Collateral Agent.

WHEREAS, under the terms of the Security Agreement, the Grantor has granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in, among other property, certain intellectual property of the Grantor, and have agreed thereunder to execute this IP Security Agreement for recording with the USPTO and/or the USCO, as applicable.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees as follows:

Section 1. Grant of Security Interest in Trademark. The Grantor hereby collaterally assigns and pledges to the Collateral Agent (and its successors and permitted assigns), for the benefit of the Secured Parties, and the Grantor hereby grants to the Collateral Agent (and its successors and permitted assigns), for the benefit of the Secured Parties, a security interest in and lien on and to all of the Grantor’s right, title and interest in and to the following, whether now owned or hereafter acquired by the undersigned (the “Trademark Collateral”):

- (a) all of its Trademarks and all IP Agreements providing for the grant by or to the Grantor of any right in, to or under any Trademark, including those referred to on Schedule 1 hereto;
- (b) all renewals and extensions of the foregoing;
- (c) all goodwill of the business connected with the use of, and symbolized by, each such Trademark; and

(d) all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof. Notwithstanding the foregoing, the Trademark Collateral shall not include and no security interest shall be granted in United States intent-to-use trademark applications prior to the filing of a "Statement of Use" pursuant to Section 1(d) of the Lanham Act or an "Amendment to Allege Use" pursuant to Section 1(c) of the Lanham Act with respect thereto, to the extent that, and solely during the period, if any, in which, the grant of a security interest therein or the assignment thereof would impair the validity or enforceability of any registration that issues from such intent-to-use application under applicable federal law).

Notwithstanding anything to the contrary contained in the foregoing clauses (a) through (d), the security interest created hereby shall not extend to, and the term "Collateral" shall not include, any Excluded Property.

Section 2. Security for Obligations. The grant of a security interest in, the Trademark Collateral by the Grantor under this IP Security Agreement secures the payment of all Secured Obligations of the Grantor now or hereafter existing under or in respect of the Secured Documents (as such Secured Documents may be amended, restated, supplemented, replaced, refinanced or otherwise modified from time to time (including any increases of the principal amount outstanding thereunder)), whether direct or indirect, absolute or contingent, and whether for principal, reimbursement obligations, interest, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise. Without limiting the generality of the foregoing, this IP Security Agreement secures, as to the Grantor, the payment of all amounts that constitute part of the Secured Obligations that would be owed by the Grantor to any Secured Party under the Secured Documents but for the fact that they are unenforceable or not allowable due to the existence of a bankruptcy, or reorganization or similar proceeding involving a Loan Party.

Section 3. Recordation. The Grantor authorizes and requests that the Commissioner for Trademarks record this IP Security Agreement.

Section 4. Grantor Remains Liable. The Grantor hereby agrees that, anything herein to the contrary notwithstanding, the Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with their Trademarks and the intellectual property licenses subject to a security interest and lien hereunder.

Section 5. Execution in Counterparts. This IP Security Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

Section 6. Grants, Rights and Remedies. This IP Security Agreement has been entered into in conjunction with the provisions of the Security Agreement. The Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Collateral Agent with respect to the Trademark Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein. In the event of any conflict or inconsistency between the terms of this IP Security Agreement and the terms of the Security Agreement, the terms of the Security Agreement shall govern.

Section 7. Governing Law; Jurisdiction; Etc.

(a) **THIS IP SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.**

(b) EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE EXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK SITTING IN NEW YORK CITY IN THE BOROUGH OF MANHATTAN AND OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK SITTING IN THE BOROUGH OF MANHATTAN, AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS IP SECURITY AGREEMENT SHALL AFFECT ANY RIGHT THAT THE COLLATERAL AGENT, ANY LENDER OR ANY L/C ISSUER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS IP SECURITY AGREEMENT OR THE RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT AGAINST ANY LOAN PARTY OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION.

(c) EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT IN ANY COURT REFERRED TO IN CLAUSE (b) OF THIS SECTION 6. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.

(d) EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 10.02 OF THE CREDIT AGREEMENT. NOTHING IN THIS IP SECURITY AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW.

(e) EACH PARTY TO THIS IP SECURITY AGREEMENT HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER THIS IP SECURITY AGREEMENT OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THIS IP SECURITY AGREEMENT, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER FOUNDED IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY TO THIS IP SECURITY AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF SECTION 10.17 OF THE CREDIT

AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE SIGNATORIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

Section 8. Status as a Loan Document. This Trademark Property Security Agreement shall constitute a Loan Document.

IN WITNESS WHEREOF, the Grantor and the Collateral Agent have caused this IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first written above.

THE LYNX GROUP, LLC

By: 

Name: Brian E. Tyburski

Title: Authorized Officer

[Signature Page to Trademark Security Agreement]

TRADEMARK
REEL: 007542 FRAME: 0168

MIDCAP FINANCIAL TRUST,
as Administrative Agent

By: Apollo Capital Management, L.P.,
its investment manager



By: Apollo Capital Management GP, LLC,
its general partner

By: 
Name: Maurice Amsellem
Title: Authorized Signatory

SCHEDULE 1
TO
TRADEMARK SECURITY AGREEMENT

1. REGISTERED TRADEMARKS AND TRADEMARK APPLICATIONS

Owner/Grantor	Trademark	Registration No./Application No.	Country
THE LYNX GROUP, LLC	AMERICAN HEALTH & DRUG BENEFITS	3,529,391	United States
THE LYNX GROUP, LLC	AMERICAN HEALTH & DRUG BENEFITS	3,503,239	United States
THE LYNX GROUP, LLC	AMYLOIDOSIS NEWS	90/706,065	United States
THE LYNX GROUP, LLC	CONQUER	5,357,418	United States
THE LYNX GROUP, LLC	CONQUER The Patient Voice Rare Disease Edition	90/787,392	United States
THE LYNX GROUP, LLC	CONSIDERATIONS IN LYMPHOMA	5,084,500	United States
THE LYNX GROUP, LLC	CONSIDERATIONS IN MULTIPLE MYELOMA	5,098,044	United States
THE LYNX GROUP, LLC	DERMATOLOGY PRACTICE MANAGEMENT	6,230,267	United States
THE LYNX GROUP, LLC	DERMATOLOGY PRACTICE MANAGEMENT	6,285,019	United States
THE LYNX GROUP, LLC	DERMATOLOGY PRACTICE MANAGEMENT	6,230,268	United States
THE LYNX GROUP, LLC	FOSTERING A DIALOGUE TO IMPROVE PATIENTCARE & OUTCOMES	4,029,791	United States
THE LYNX GROUP, LLC	IMMUNOTHERAPY IN ONCOLOGY	4,749,801	United States
THE LYNX GROUP, LLC	IMMUNOTHERAPY IN ONCOLOGY	97/154,897	United States
THE LYNX GROUP, LLC	INTERACTIVE PEER-TO-PEER DISCUSSIONS IN HEMATOLOGY/ONCOLOGY	3,617,783	United States
THE LYNX GROUP, LLC	JOURNAL OF HEMATOLOGY ONCOLOGY PHARMACY	90/705,915	United States
THE LYNX GROUP, LLC	JOURNAL OF HEMATOLOGY ONCOLOGY PHARMACY	90/705,904	United States

THE LYNX GROUP, LLC	JOURNAL OF ONCOLOGY NAVIGATION & SURVIVORSHIP	6,384,889	United States
THE LYNX GROUP, LLC	JOURNAL OF ONCOLOGY NAVIGATION & SURVIVORSHIP	6,384,890	United States
THE LYNX GROUP, LLC	ONCOLOGY PRACTICE MANAGEMENT	6,274,430	United States
THE LYNX GROUP, LLC	ONCOLOGY PRACTICE MANAGEMENT	6,191,739	United States
THE LYNX GROUP, LLC	ONCOLOGY PRACTICE MANAGEMENT	6,191,738	United States
THE LYNX GROUP, LLC	RESOURCE NAVIGATOR	90/779,730	United States
THE LYNX GROUP, LLC	RHEUMATOLOGY PRACTICE MANAGEMENT	6,218,683	United States
THE LYNX GROUP, LLC	RHEUMATOLOGY PRACTICE MANAGEMENT	6,230,269	United States
THE LYNX GROUP, LLC	RHEUMATOLOGY PRACTICE MANAGEMENT	85/539,871	United States
THE LYNX GROUP, LLC	RX PROFILER	4,290,377	United States
THE LYNX GROUP, LLC	RX PROFILER	4,188,210	United States
THE LYNX GROUP, LLC	STRATEGIX	90/021,974	United States
THE LYNX GROUP, LLC	STRATEGIX	90/975,741	United States
THE LYNX GROUP, LLC	STRATEGIX (stylized and/or with design) 	90/051,366	United States
THE LYNX GROUP, LLC	STRATEGIX (stylized and/or with design) 	90/975,742	United States
THE LYNX GROUP, LLC	THE JOURNAL OF ONCOLOGY NAVIGATION & SURVIVORSHIP	4,024,121	United States
THE LYNX GROUP, LLC	THE LYNX GROUP	90/021,979	United States
THE LYNX GROUP, LLC	THE LYNX GROUP (stylized and/or with design) 	90/051,354	United States
THE LYNX GROUP, LLC	THE ONCOLOGY NURSE-APN/PA	4,017,380	United States
THE LYNX GROUP, LLC	THE ONCOLOGY NURSE-APN/PA	4,014,148	United States
THE LYNX GROUP, LLC	THE ONCOLOGY NURSE-APN/PA	4,017,379	United States

THE LYNX GROUP, LLC	THE ONCOLOGY NURSE-APN/PA	4,017,381	United States
THE LYNX GROUP, LLC	THE ONCOLOGY PHARMACIST	3,555,609	United States
THE LYNX GROUP, LLC	THE ONCOLOGY PHARMACIST	3,555,608	United States
THE LYNX GROUP, LLC	THE UROLOGY NURSE-NP/PA	4,107,003	United States
THE LYNX GROUP, LLC	THE UROLOGY NURSE-NP/PA	4,107,004	United States
THE LYNX GROUP, LLC	UROLOGY PRACTICE MANAGEMENT	85/537,400	United States
THE LYNX GROUP, LLC	UROLOGY PRACTICE MANAGEMENT	85/537,390	United States
THE LYNX GROUP, LLC	UROLOGY PRACTICE MANAGEMENT	85/537,462	United States
THE LYNX GROUP, LLC	VALUE-BASED CANCER CARE	3,918,281	United States
THE LYNX GROUP, LLC	VALUE-BASED CANCER CARE	3,918,282	United States